Literature DB >> 32959758

Case Report: Visceral Leishmaniasis Falsely Diagnosed as Q Fever.

Ankush Dhariwal1, Sarah Jawad2, Tihana Bicanic2.   

Abstract

Visceral leishmaniasis (VL) is a systemic infection caused by the protozoal parasite Leishmania, spread via the bloodstream to the reticuloendothelial system, through the bite of the sand fly. It is endemic in parts of Africa, South America, Asia, and Europe, including the Mediterranean. Here, we describe a case of VL that was initially diagnosed as Q fever based on positive Coxiella burnetii serology and showed a partial response to doxycycline treatment.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32959758      PMCID： PMC7646819          DOI： 10.4269/ajtmh.19-0731

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN： 0002-9637            Impact factor:   2.345


  11 in total

1.  Revival of tetracyclines--in the treatment of visceral leishmaniasis?

Authors:  K Heer; D Pfister; V Briner
Journal:  Schweiz Med Wochenschr       Date:  1999-05-29

2.  Low antibodies titer and serological cross-reaction between Coxiella burnetii and Legionella pneumophila challenge the diagnosis of mediastinitis, an emerging Q fever clinical entity.

Authors:  Sophie Edouard; Matthieu Million; Jean-Paul Casalta; Frédéric Collart; Bernard Amphoux; Didier Raoult
Journal:  Infection       Date:  2017-08-04       Impact factor: 3.553

3.  Bartonella quintana endocarditis with positive serology for Coxiella burnetii.

Authors:  Joseph Rahimian; Didier Raoult; Yi-Wei Tang; Bruce A Hanna
Journal:  J Infect       Date:  2005-12-27       Impact factor: 6.072

4.  Sensitivity of bone marrow aspirates in the diagnosis of visceral leishmaniasis.

Authors:  Mauro Roberto B da Silva; Jay M Stewart; Carlos Henrique N Costa
Journal:  Am J Trop Med Hyg       Date:  2005-06       Impact factor: 2.345

5.  Liposomes in leishmaniasis: therapeutic effects of antimonial drugs, 8-aminoquinolines, and tetracycline.

Authors:  C R Alving; E A Steck; W L Chapman; V B Waits; L D Hendricks; G M Swartz; W L Hanson
Journal:  Life Sci       Date:  1980-06-30       Impact factor: 5.037

6.  Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?

Authors:  Niven A Salih; Johan van Griensven; François Chappuis; Annick Antierens; Ann Mumina; Omar Hammam; Philippa Boulle; Emilie Alirol; Mubarak Alnour; Mousab S Elhag; Marcel Manzi; Walter Kizito; Rony Zachariah
Journal:  Trop Med Int Health       Date:  2014-01-17       Impact factor: 2.622

7.  Comparison of PCR with direct examination of bone marrow aspiration, myeloculture, and serology for diagnosis of visceral Leishmaniasis in immunocompromised patients.

Authors:  R Piarroux; F Gambarelli; H Dumon; M Fontes; S Dunan; C Mary; B Toga; M Quilici
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

8.  Kala-azar: a comparative study of parasitological methods and the direct agglutination test in diagnosis.

Authors:  E E Zijlstra; M S Ali; A M el-Hassan; I A el-Toum; M Satti; H W Ghalib; P A Kager
Journal:  Trans R Soc Trop Med Hyg       Date:  1992 Sep-Oct       Impact factor: 2.184

9.  Doxycycline for the treatment of cutaneous leishmaniasis.

Authors:  A Masmoudi; A Dammak; H Chaaben; N Maalej; F Akrout; H Turki
Journal:  Dermatol Online J       Date:  2008-08-15

10.  Evaluation of serological tests to identify Trypanosoma cruzi infection in humans and determine cross-reactivity with Trypanosoma rangeli and Leishmania spp.

Authors:  Zuleima C Caballero; Octavio E Sousa; Waldelania P Marques; Amadeo Saez-Alquezar; Eufrosina S Umezawa
Journal:  Clin Vaccine Immunol       Date:  2007-05-23
View more
  1 in total

1.  Visceral and mucosal leishmaniasis mimicking Wilson disease and oral neoplasia.

Authors:  Carlo Bova; Andrea de Vuono; Martina Ruvio; Francesca Serena Pignataro; Elio Fiaschi
Journal:  IDCases       Date:  2022-03-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.